Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
Ингибиторы CD73-аденозинергического контрольного пути как перспективные комбинированные препараты для традиционной и передовой иммунотерапии рака
2023-06-26
SCID: 54.1/bpv7sr89
Discuss with AI
A2AR/A2BR antagonistsCD73-adenosinergic immune checkpointPD-1/PD-L1 blockadeextracellular adenosinetumor microenvironment
Figures from the paper
Abstract (AI)
The cell surface enzyme CD73 is increasingly appreciated as a pivotal non-redundant immune checkpoint (IC) in addition to PD-1/PD-L1 and CTLA-4. CD73 produces extracellular adenosine (eADO), which not only inhibits antitumor T cell activity via the adenosine receptor (AR) A2AR, but also enhances the immune inhibitory function of cancer-associated fibroblasts and myeloid cells via A2BR. Preclinical studies show that inhibition of the CD73-adenosinergic pathway in experimental models of many solid tumors either as a monotherapy or, more effectively, in combination with PD-1/PD-L1 or CTLA-4 IC blockades, improves antitumor immunity and tumor control. Consequently, approximately 50 ongoing phase I/II clinical trials targeting the CD73-adenosinergic IC are currently listed on https://clinicaltrials.gov . Most of the listed trials employ CD73 inhibitors or anti-CD73 antibodies alone, in combination with A2AR antagonists, and/or with PD-1/PD-L1 blockade. Recent evidence suggests that the distribution of CD73, A2AR and A2BR in tumor microenvironments (TME) is heterogeneous, and this distribution affects CD73-adenosinergic IC function. The new insights have implications for the optimally effective, carefully tailored approaches to therapeutic targeting of this essential IC. In the mini-review, we briefly discuss the cellular and molecular mechanisms of CD73/eADO-mediated immunosuppression during tumor progression and therapy in the spatial context of the TME. We include preclinical data regarding therapeutic CD73-eADO blockade in tumor models as well as available clinical data from completed trials that targeted CD73-adenosinergic IC with or without PD-1/PD-L1 inhibitors and discuss factors that are potentially important for optimal therapeutic outcomes in cancer patients.
Key Findings
1
Approximately 50 phase I/II clinical trials are investigating CD73-adenosinergic checkpoint targeting, commonly using CD73 inhibitors or antibodies alone or combined with A2AR antagonists and PD-1/PD-L1 blockade.
2
CD73 functions as a non-redundant immune checkpoint by generating extracellular adenosine that suppresses antitumor T cells through A2AR and strengthens fibroblast and myeloid-cell immunosuppression through A2BR.
3
CD73, A2AR, and A2BR are heterogeneously distributed within tumor microenvironments, influencing checkpoint activity and requiring spatially tailored therapeutic strategies.
4
Preclinical inhibition of the CD73-adenosinergic pathway improves antitumor immunity and tumor control across multiple solid-tumor models, especially when combined with PD-1/PD-L1 or CTLA-4 blockade.
5
The review integrates mechanistic, preclinical, and available clinical evidence to identify factors that may determine optimal outcomes from CD73-adenosinergic checkpoint therapies.
Research Object
CD73–adenosinergic immune checkpoint in the tumor microenvironment of solid tumors
Research Subject
Cellular and molecular mechanisms of CD73/eADO-mediated immunosuppression and the therapeutic efficacy, combinations, and spatially tailored application of CD73–adenosinergic checkpoint inhibitors
Publication Details
Publication Date
2023-06-26
Journal
Publisher
ISSN
Cited by
51
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest